Third quarter total revenue of $160 million, Crysvita® revenue of$112 million and Dojolvi® revenue of $24 million Reaffirm 2025 Revenue Guidance: Total revenue between$640 million to $670 million, Crysvita revenue of$460 million to $480 million, and Dojolvi revenue of$90 million to $100 million Bolstered balance sheet with$400 million proceeds from sale of portion of Crysvita royalty interest NOVATO, Calif., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceu ...